Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS

NCT01995981 is registered in ClinicalTrials.gov with Radboud University Medical Center as lead sponsor.

NCT NCT01995981
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01995981 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS
Lead sponsor
Radboud University Medical Center
Phase
Observational
Overall status
Completed
Start date
December 31, 2013
Completion date
November 10, 2017
Enrollment
22 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma, soft tissue